The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| IOBT | -7.01% | N/A | N/A | -95% |
| S&P | +13.19% | +87.83% | +13.42% | +43% |
IO Biotech, Inc. engages in the development of immune modulating cancer therapies based on its T-win technology platform. Its platform is a novel approach to cancer immunotherapy designed to activate naturally occurring T cells to target immunosuppressive mechanisms. The company was founded by Mai-Britt Zocca, Inge Marie Svane, and Mads Hald Andersen in December 2014 and is headquartered in Copenhagen, Denmark.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.23M | -12.2% |
| Market Cap | $23.92M | -65.4% |
| Market Cap / Employee | $0.31M | 0.0% |
| Employees | 78 | 0.0% |
| Net Income | -$8.38M | 65.1% |
| EBITDA | -$19.13M | 27.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $30.66M | -61.8% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $17.33M | 1208.0% |
| Short Term Debt | $0.79M | 13.5% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -136.03% | -67.2% |
| Return On Invested Capital | -161.42% | -185.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$18.48M | 11.2% |
| Operating Free Cash Flow | -$18.48M | 11.2% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.84 | 1.53 | 3.47 | 15.03 | 1991.72% |
| Price to Tangible Book Value | 0.84 | 1.53 | 3.47 | 15.03 | 1991.30% |
| Enterprise Value to EBITDA | -0.09 | -1.63 | -3.13 | -0.61 | -279.88% |
| Return on Equity | -106.0% | -138.8% | -212.5% | -240.5% | 206.34% |
| Total Debt | $1.92M | $1.76M | $8.36M | $18.12M | 797.42% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
